SAN DIEGO--(BUSINESS WIRE)--BeneChill, Inc. (“BeneChill”, the “Company”) is pleased to announce the appointment of Elmar Landwehr as Managing Director for the EMEA region. Mr. Landwehr, who previously served in a sales and marketing capacity, will now assume a leadership role overseeing all of the logistical, legal entity, and managerial activities for BeneChill Europe. Mr. Landwehr’s responsibilities were expanded due to the recent retirement of Mr. Wolfgang Karl, Vice President of Sales and Marketing for the EMEA. Mr. Landwehr will report to Fred Colen, BeneChill’s Chief Executive Officer, who is based in the US.
Mr. Landwehr is a seasoned professional with nearly 30 years experience working for major pharmaceutical and medical device companies. He previously held senior marketing and business positions at Schwarz Pharma AG (marketing manager), Sterimed Inc. (business manager), AVE Arterial Vascular Engineering Inc (business manager), Medtronic AG (business manager), EV 3 GmbH (business manager), and ELan Medical Technologies GmbH (managing director).
During his tenure as managing director at ELan, Mr. Landwehr was the exclusive distributor for the temperature management devices of Alsius Corporation. Mr. Landwehr successfully launched Alsius’ CoolGard and ThermoGard systems into the market. Mr. Landwehr continued to lead the sales efforts for these products until Alsius was acquired by ZOLL Medical Corporation.
"I am pleased to be expanding my role at BeneChill. I look forward to building out the full potential of the RhinoChill® platform. My collective experience in business management, product marketing, and cooling device technology allows me to realize the full potential of the RhinoChill® platform. I am looking forward to continuing to build upon what our team has already achieved to make RhinoChill® a best-in-class cooling solution,” stated Elmar Landwehr.
“We are pleased that Mr. Landwehr will be taking on greater involvement with BeneChill in both EMEA business development and sales and marketing capacities,” stated Fred Colen, CEO of BeneChill. “Mr. Landwehr’s well-rounded career, coupled with his existing experience at BeneChill and with the RhinoChill® platform, allows us to stay on target with our growth trajectory and our business goals in Europe and the EMEA region.”
About BeneChill, Inc.
BeneChill, Inc. is a medical device company established in 2003 to develop, manufacture, and sell novel rapid cooling products to improve clinical outcomes. BeneChill’s lead product, the RhinoChill® IntraNasal Cooling System (also referred to as the RhinoChill® System, “RhinoChill®”, or the “System”), is designed to deliver targeted, effective and therapeutically beneficial cooling to the nasal cavity and the brain (and to the body via the cooled brain, if so desired). Utilizing a lightweight, portable system design and unique intra-nasal, catheter-based delivery of a quickly evaporating coolant, BeneChill offers a unique opportunity for medical practitioners to protect the brain. BeneChill’s cooling technology is also suitable for applications on conscious patients where a local, short duration cooling of the nasal cavity is of therapeutic benefit, such as for the treatment of acute migraine. BeneChill’s treatment can also be used during Cardiac Arrest, potentially during Traumatic Brain Injury and may be applicable for other surgical procedures. BeneChill is headquartered in San Diego, CA with European locations near Zürich, Switzerland and Düsseldorf, Germany. BeneChill products, while CE marked in Europe for cooling application, are not FDA approved and not available in the US. For further information please visit www.benechill.com.
Safe Harbor:
Certain matters discussed in this release may constitute forward looking statements for the purposes of the Federal Securities Laws, and as such, may involve known and unknown risk. Uncertainties and other factors may cause actual results, performance or activities of BeneChill, Inc. to be materially different from future results of performance or achievements expressed or implied by such forward looking statements. Additional information concerning factors that could cause actual results to be materially different than those in forward looking statements can be found in BeneChill, Inc.’s filings with the Securities and Exchange Commission (SEC). All forward-looking statements are expressly qualified in their entirety by these cautionary statements.
